Does cilengitide deserve another chance?

The Lancet Oncology

Volumn 15, Issue 13, 2014, Pages e584-e585

  Tucci, Marco ^a   Stucci, Stefania ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; CILENGITIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; VITRONECTIN RECEPTOR; DACARBAZINE; DNA METHYLTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SNAKE VENOM; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; BONE METASTASIS; BREAST CANCER; CANCER RECURRENCE; CELL PROLIFERATION; DRUG HALF LIFE; ENZYME ACTIVATION; ENZYME INHIBITION; GLIOBLASTOMA; HEAD AND NECK TUMOR; HUMAN; INTRACELLULAR SIGNALING; LETTER; LOW DRUG DOSE; LUNG CANCER; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; OPEN STUDY; OSTEOCLAST; OSTEOCLASTOGENESIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN METHYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; FEMALE; GENETICS; MALE;

BRAIN NEOPLASMS; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; SNAKE VENOMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84925228193     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70462-0     Document Type: Letter

References (5)

1. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phese 3 trial. Lancet Oncol 2014, 15:1100-1108. for the European Organisation for Research and Treatment of Cancer (EORTC), the Canadian Brain Tumor Consortiumthe Canadian Brain Tumor Consortium, the CENTRIC study teamthe CENTRIC study team.
2. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 2011, 7:339-354.
3. Bäuerle T, Komlijenovic D, Merz M, Berger MR, Goodman SL, Semmler W Cilengitide inhibits progression of experimental breast cancer bone metastasis as imaged non invasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 2011, 128:2453-2462.
4. Tucci M, De Palma R, Lombardi L, et al. β3 integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res 2009, 69:6738-6746.
5. Stucci LS, Tucci M, Vecchio M, et al. The αVβ3/αVβ5 blockage by Cilengitide disables the osteoclast-like differentiation of malignant plasma cells in multiple myeloma. Eur J Cancer 2013, 49(suppl 2):S759-S892.